A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study

Table 2 Recommended LMWH dose levels

LMWH	Month one	Month two to six	Entry to ALICAT
Dalteparin (Fragmin^®)	200 International Units/kg total body weight, once daily	150 International Units/kg total body weight, once daily	Dose as detailed at month six
Tinzaparin (Innohep^®)	175 International Units/kg total body weight, once daily	175 International Units/kg total body weight, once daily	Dose as detailed at month six
Enoxaparin (Clexane^®)	150 International Units/kg total body weight, once daily	150 International Units/kg total body weight, once daily	Dose as detailed at month six

ALICAT, Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis; LMWH, Low molecular weight heparin; kg, kilogram.

ISSN: 1745-6215